Sanofi granted EU licensing for Dupixent
admin 10th May 2019 Uncategorised 0The approval marks the first biologic licensed in the EU for severe asthma with type II inflammation. More: Sanofi granted EU licensing for Dupixent Source: News
read more
The approval marks the first biologic licensed in the EU for severe asthma with type II inflammation. More: Sanofi granted EU licensing for Dupixent Source: News
read moreLupus affects 5 million patients worldwide, predominantly female. More: World Lupus Day: new report reveals need for care improvements Source: News
read moreAs SGLT2 drugmakers count on the blockbuster diabetes drugs for growth, a team of researchers has tracked dozens of cases of Fournier’s gangrene, a flesh-eating bacterial infection in the genitals, among patients using the drugs. More: Researchers warn about gangrene
read moreWith an Ebola outbreak in Congo outrunning vaccination efforts to control it and the supplies of Merck’s Ebola vaccine on hand, the World Health Organization will give smaller vaccine doses and also use an experimental drug from Johnson & Johnson.
read moreNovartis’ initial jump into cell and gene therapies with pioneering CAR-T drug Kymriah has run into manufacturing challenges that have slowed expansion in the U.S. But with approval of its second gene therapy expected by the end of the month,
read moreRoche’s MS superstar Ocrevus has run into few obstacles on its path to nearly $1 billion in global sales this year. Now, one major hurdle on the drug’s blockbuster journey—England’s cost watchdogs—has dropped. More: Roche's Ocrevus continues winning streak as
read more© 1994 - 2026 B.M. Pharmaceuticals